Immobilized-enzyme reactors are beginning to be studied for a variety of therapeutic applications. To facilitate the design of these devices for different clinical situations and a diverse patient population, mathematical models may be valuable. An immobilized-heparinase (EC 4.2.2.7) reactor was selected as a model system. The device removes heparin from blood that has been anticoagulated to prevent thrombus formation. Heparinase was immobilized to crosslinked agarose particles. A mathematical model was developed to describe the clearance of heparin by the reactor ex vivo and compared to experimental clearances measured in sheep. The model accounted for enzymatic degradation as well as the binding of heparin and its breakdown products to antithrombin. The device was modeled as a steady-state continuously stirred tank reactor. Molar conservation equations within the agarose particles accounted for simultaneous diffusion and chemical reaction. The model had no adjustable parameters and was able to predict the clearance of heparin within 5-25% for three different animals and 12 different perfusions.
Therapeutic applications of immobilized enzymes have been proposed for a variety of clinical situations ranging from cancer therapy to the treatment of neonatal jaundice (1-3). In all cases an immobilized-enzyme reactor serves as a drug-or toxin-removal system. The clinical application and the patient requirements determine the reactor size necessary to clear the agent from the blood. This wide range of device specifications is an obstacle to their gaining widespread usage. Mathematical models of the performance of enzyme reactors can potentially eliminate this problem by facilitating the design of devices for different clinical situations.
Previous modeling of enzyme reactors has been attempted in systems that have been studied with saline or buffer as the medium (4) (5) (6) . Systems perfused with blood are more complex, since blood proteins can serve as carrier molecules for hydrophobic or ionic substrate molecules. Analysis of such systems may require treating the free and unbound forms of the substrate separately, since the substrate-protein complex can behave differently than the free substrate.
As a first step to developing models of enzyme reactors that are applicable to operation in blood, a particular system, immobilized heparinase (EC 4.2.2.7), was selected for mathematical analysis. Heparinase degrades the drug heparin, which is required to fully anticoagulate patients undergoing extracorporeal therapy (e.g., hemodialysis or membrane oxygenation) to prevent clotting within the extracorporeal circuit. Heparin is cleaved to nontoxic low molecular weight fragments that have much less anticoagulant activity than the parent compound heparin both in vitro and ex vivo (7, 8) .
Heparinase was covalently immobilized to agarose to prevent the direct in vivo introduction of the enzyme as well as to enhance its stability (9) . The gel is placed in an arterial blood filter through which the blood is passed and the heparin is degraded (10) . The filter contains a 25-,pm-cutoff internal mesh, which prevents the gel from leaving the device.
The present work was concerned with the formulation of a model of the heparinase reactor. Model Fig. 2 . The model is formulated by writing molar conservation equations for all species both inside the agarose particles and within the bulk phase of the reactor (11, 12) . The two are coupled and solved simultaneously.
Heparin binds to one of the proteins in the blood, antithrombin (13 [3] [4] [5] where Di is the effective diffusivity of species i within the particle, Ci is the concentration of species i per volume of fluid/plasma at position r, R1 is the volumetric rate of production of heparin by reaction I, R2 is the volumetric rate of production of heparin by reaction II, R3 is the volumetric rate of product formation by reaction Im, and
The reaction rates are based on the total gel volume.
For each chemical species boundary conditions are r0= dCj/dr= 0 r = ro -Dj (dCj/dr) = kj(Cj -Cje), [6] [7]
where kj is the mass-transfer coefficient of speciesj, ro is the radius of an agarose particle, and Cje is the concentration of species j in the bulk phase at the reactor outlet. The kinetics of heparin degradation (reaction I) follow Michaelis-Menten kinetics (16) :
where n is the number of moles of product generated. The heparin-antithrombin complex is assumed to be sterically inhibited from binding to immobilized heparinase, and under these conditions only unbound heparin is enzymatically degraded. As unbound heparin is consumed, heparin dissociates from the heparin-antithrombin complex to generate more free heparin.
The breakdown of heparin results in a distribution of low molecular weight fragments ranging in size from a disaccharide to an octasaccharide (7) . Except for the disaccharides, the other products can bind to antithrombin with affinities that depend on their molecular weight (14, 15) . Of these, only the octasaccharide binds to antithrombin to any significant degree and thus is the only product that must be considered in the modeling. The binding process is represented by the following reversible chemical reaction.
As octasaccharide products are generated, they diffuse out of the agarose particles as well as compete for the binding site on the antithrombin molecule. Heparin is displaced from antithrombin by the product and the concentration of unbound heparin available for degradation is increased.
Molar conservation equations are written for species within the particle: heparin (H), octasaccharide (P), antithrombin (A), the heparin-antithrombin complex (AH), and the octasaccharide-antithrombin complex (AP) (letters in parentheses refer to the subscript notation used for the model formulation). The transport of speciesj within the catalytic particle is assumed to occur by diffusion only. Steady-state conservation equations for each species are written as follows: [8] where CH is the heparin concentration and Vmax = kcatE(t), [9] where kcat is the catalytic constant. E(t) is the concentration of active immobilized heparinase at time t: E(t) = Eoexp(-kdt), [10] where Eo is the enzyme concentration at time zero and kd is the first-order deactivation constant.
The total heparin concentration is obtained by summing the conservation equations for heparin and the heparin-antithrombin complex. In [11] The boundary condition at the center of the agarose particle remains the same, while that at the particle surface becomes Studies using blue dextran as a tracer have shown the heparinase reactor to behave as a wellmixed reactor in buffer (16) , and the same behavior is assumed ex vivo. The first issue to consider is whether the heparinase system is operating at a steady state.
A regional heparinization scheme is used, with heparin slowly dripped into the arterial line at point A (Fig. 3) . The heparinized blood then passes through the reactor and back to the animal via the venous line. The heparin concentration in the blood entering the reactor is determined by both the rate of heparin infused and the animal's arterial heparin level. The animal's heparin level depends on the clearance of heparin by the filter and the animal's endogenous heparin metabolism. Thus the heparin concentration entering the reactor may not be constant and the reactor may not be operating at a steady state. The second way in which the reactor steady state can be perturbed is due to enzyme deactivation.
Experimentally, the concentration of heparin does not vary by more than 20% over the course of a 1-hr experiment (10) . The rate of enzyme deactivation is on the order of hours (9) . The characteristic response time for an immobilized-enzyme particle can be calculated as 3 sec (18) . This is much shorter than the time frame over which the changes in the plasma heparin and immobilized enzyme concentrations are occurring. Thus, for modeling purposes, the variations in the inlet heparin concentration and the immobilized-heparinase concentration are not considered to affect the steady state of the reactor. Under these conditions, the time dependence of the heparin and enzyme concentrations are substituted directly into the steady-state design equation.
The metabolism of the heparin breakdown products has been studied and at a dose of 1 mg/ml, the products were excreted and cleared from the bloodsteam within minutes (8) . The metabolism of the products is dose-dependent with the clearance rate increasing as the dose is lowered (19) . The degradation-product concentrations anticipated in these studies are much lower than 1 mg/ml and the products would be cleared at a faster rate. Thus the concentration of heparin breakdown products in the sheep and in the blood entering the reactor would be negligible. A steady-state balance for total heparin (bound and unbound) in a well-mixed reactor is given by (1 -Hct)Q[(CH + CAH)e -(CH + CAH)i] = ReVb, [14] where Q is the blood flow rate, Hct is the hematocrit, Vb is the volume of catalyst, Re is the overall rate of total heparin degradation by reactions I and II, and the subscripts i and e refer to the inlet and outlet of the reactor. The overall reac- tion rate (Re) is related to the total heparin flux into the catalytic particle as follows: [16]
Model Parameters and Solution. As a first approximation to the kinetic behavior of immobilized heparinase in blood, the kinetic constants of the enzyme measured in buffer were utilized (16) . The diffusion coefficients and the mass-transfer coefficients were estimated from the literature (20, 21) . For each mole of heparin degraded, 0.8 mol of octasaccharide is produced (7). The equilibrium constant for binding of heparin to antithrombin was taken as 5.7 x 10-8 M (17) and that for binding of the octasaccharide to antithrombin was taken as 1.8 x 10-6 M (15). The half-life of the immobilized heparinase in the reactor was determined as described below and used to calculate the first-order deactivation constant (Eq. 10) as follows: kd = ln(2)/t½, [17] where t½ is the half-life of the immobilized enzyme. The reactor balance and the particle concentration profiles were solved simultaneously by using a fourth-order Runge Kutta integration technique (22) .
MATERIALS AND METHODS
Immobilized-Enzyme Preparation. Flavobacterium heparinum was grown according to the procedure of Galliher et al. (23) . Heparinase was prepared by hydroxylapatite chromatography and QAE-Sephadex chromatography (24) and was immobilized to cyanogen bromide-activated, 8% crosslinked agarose (10) . The activity of heparinase in buffer was measured by following the appearance of heparin degradation products at 232 nm (10) . One unit of activity is defined as the amount of heparinase that fully degrades 1 mg of heparin per hour.
Reactor Fabrication and Circuit Setup. A 250-ml blood filter (model AF-10; American Hospital Supplies, Irvine, CA) was used as the reactor. The filter was modified by the insertion of a recirculation line, which was connected to a secondary peristaltic pump as shown in Fig. 1 . This serves to direct the fluid in multiple directions and to enhance mixing within the device. The agarose particles are prevented from leaving the reactor by an internal 25-gm-cutoff polyester mesh (10) .
The blood flow for all experiments was 120 ml/min.
The experiments were conducted on adult female sheep with Thomas arteriovenous shunts. Four experiments were performed on each animal. Heparin was continuously infused into the arterial tubing at 10,000 USP units/hr with a syringe infusion pump (Harvard Co., Millis, MA).
Blood samples for heparin monitoring were taken in duplicate from two injection ports, before and after the reactor (points B and C in Fig. 3 ). Blood sampling began after all the priming saline had been washed out of the circuit. This was marked by the time at which the animal's concentration of heparin had stabilized, which normally required 20 min. The length of each experiment was 1 hr, and heparin clearance data were acquired for 40 min of the 1-hr experiment. Plasma heparin levels were determined by the aPTT (activated partial thromboplastin time) clotting assay (10) . The heparin degradation products do not possess any significant activity by the aPTT assay (7). Each sample was assayed in triplicate 8754 Physiological Sciences: Bernstein and Langer and the measurement error in heparin concentration was <3%. The concentration of antithrombin III was measured by radioimmunodiffusion (25) .
Reactor Half-Life. The enzymatic activity of the reactor can decrease with time due to a decrease in the fraction of active enzyme and the clumping of the agarose gel, which decreases the available catalytic activity of the device. The heparin clearance is proportional to the concentration of active immobilized heparinase, and thus the decline in enzymatic activity was measured by following the heparin clearance with time. A series of experiments was conducted to measure the decline in heparin clearance with time in sheep blood in vitro, with the concentration of heparin entering the reactor, the volume of immobilized heparinase, and the blood flow held constant.
RESULTS
The clearance of heparin in vitro decreased according to first-order kinetics with a half-life of 31 ± 3 minutes (n = 3) (Fig. 4) . The deactivation constant was as 2.2 x 10-2 min-i as calculated from Eq. 17.
To test the model predictions, the single-pass clearance of heparin was determined as a function of time in three sheep. For each experiment, the volume of beads, the initial enzyme loading, the animal's antithrombin level, the hematocrit, the inlet heparin concentration, and the half-life of the enzyme were used to generate the model predictions for the clearance of heparin as a function of time; The model results are based on the parameter values summarized in Table 1 . The antithrombin levels and hematocrits for the three sheep are summarized in Table 2 .
Two types of control experiments were conducted to determine the amount of heparin nonspecifically removed from the extracorporeal circuit. The control reactors contained either plain agarose or agarose with heat-inactivated immobilized heparinase. Both types of control reactors resulted in less than a 2% difference between the inlet and the outlet heparin activity. This is on the same order as the measurement error for heparin, and thus nonspecific removal of hep- 6.4 x 10-4 K1 = 5.8 x 10-8 M; K3 = 1.8 x 106M;Km =0.15 mg/ml; Q = 120 ml/min. *Mass-transfer coefficient.
arn was considered negligible. All decreases in heparin activity across the reactor were thus attributed to enzymatic degradation.
Four experiments were conducted on each of the three sheep, and the model predictions are shown together with the experimental data in Fig. 5 . The clearances were in the range 36-72 ml/min, depending on the animal and the concentration of heparinase on the beads. The model clearances were within 5-25% of the experimentally determined values.
When the reactor performances for the three sheep were compared at similar heparinase concentrations and volumes, the clearances were highest for the sheep with the lowest antithrombin concentration. The The mass-transfer coefficients were varied between the limiting cases of stagnant flow in the reactor to no masstransfer resistance at the particle/fluid interface (21) . A drop in the coefficient to the value for stagnant flow led to at most a 9% drop in clearance over the range of heparinase concentrations 100-200 units/ml. When the coefficient was increased to the value for no mass-transfer resistance, a 2% increase in the clearance was noted. Thus the model is not significantly influenced by uncertainties in the mass-transfer coefficients.
The heparin binding constant was varied between 5 x 10-8 M and 18 x 10-8 M, which are the lower and upper limits of the reported binding constants (17, 26) . As the equilibrium constant is decreased, a higher percentage of the total heparin is bound to antithrombin. The free heparin concentration is lower and less heparin is available for enzymatic degradation, leading to a lower clearance. As the binding constant The octasaccharide binding constant was varied between values a factor of 10 above and below the reference value (1.8 x 10-6 M) shown in the legend-of Table 1 . The octasaccharide product competes for the binding site on antithrombin. As the binding constant is decreased, the affinity of the product for antithrombin increases and more heparin is displaced from the antithrombin. The free heparmn concentration increases, resulting in a higher local reaction rate and a greater heparin clearance by the device. The decrease in the product binding constant by a factor of 10 resulted in only an 8% increase in the clearance, whereas a 10-fold increase led to a 5% decrease in clearance. The small effect on the clearance is attributed to the binding constant for the octasaccharide being only 1/36th of that for heparin (15, 17) . Thus unless the binding constant is in error by a factor of 36 or more, the uncertainty in the product binding constant should have little effect on the model predictions.
The ability to predict clearance for immobilized heparinase will be useful in the design of different reactors operating at different flow rates and capacities for such diverse operations as open heart surgery, hemofiltration, hemodialysis, and membrane oxygenation for both children and adults. In addition, the methods used to develop the model for this reactor may prove useful as other extracorporeal reactors employing enzymes and antibodies are developed. 
